On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Laurie H. Sehn

ResearcherPublications, citations & collaboration network

Laurie H. Sehn is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does Laurie H. Sehn have?

ScholarIQindexed works

Laurie H. Sehn has 657 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does Laurie H. Sehn have?

ScholarIQcitation count

Laurie H. Sehn has 31,023 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of Laurie H. Sehn?

ScholarIQh-index

Laurie H. Sehn has an h-index of 84 in OpenAlex.

What is the i10-index of Laurie H. Sehn?

ScholarIQi10-index

Laurie H. Sehn has an i10-index of 283 in OpenAlex.

What is the ORCID of Laurie H. Sehn?

ScholarIQorcid

The ORCID for Laurie H. Sehn is on the source record.

What is the OpenAlex record for Laurie H. Sehn?

ScholarIQopenalex

The OpenAlex for Laurie H. Sehn is on the source record.

What are the most-cited papers on Laurie H. Sehn?

ScholarIQmost cited works
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era
Zheng Zhou, Laurie H. Sehn, Alfred Rademaker, Leo I. Gordon, Ann S. LaCasce, Allison Crosby‐Thompson, Ann Vanderplas, Andrew D. Zelenetz, Gregory A. Abel, Maria Alma Rodriguez, Auayporn Nademanee, Mark Kaminski, Myron S. Czuczman, Michael Millenson, Joyce C. Niland, Randy D. Gascoyne, Joseph M. Connors, Jonathan W. Friedberg, Jane N. Winter
Blood. 2013959 Citations
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Manali Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhıt Özcan, Jamie Hirata, Elicia Penuel, Joseph N. Paulson, Ji Cheng, Grace Ku, Matthew J. Matasar
Journal of Clinical Oncology. 2019780 CitationsOPEN ACCESS
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Franck Morschhauser, Nathan Fowler, Pierre Feugier, Réda Bouabdallah, Hervé Tilly, M. Lia Palomba, Christophe Fruchart, Edward N. Libby, Olivier Casasnovas, Ian W. Flinn, Corinne Haïoun, Hervé Maisonneuve, Loïc Ysebaert, Nancy L. Bartlett, Kamal Bouabdallah, Pauline Brice, Vincent Ribrag, Nicolas Daguindau, Steven Le Gouill, Gian M. Pica, Alejandro Martı́n, Armando López‐Guillermo, Jean-François Larouche, Kiyoshi Ando, María Gomes da Silva, Marc André, Pierre Zachée, Laurie H. Sehn, Kensei Tobinai, Guillaume Cartron, David Liu, Jianming Wang, Luc Xerri, Gilles Salles
New England Journal of Medicine. 2018366 CitationsOPEN ACCESS
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, Sarit Assouline, Laurie H. Sehn, Ian W. Flinn, Manish R. Patel, Randeep Sangha, Anton Hagenbeek, Ranjana H. Advani, Hervé Tilly, Olivier Casasnovas, Oliver W. Press, Sreeni Yalamanchili, Robert S. Kahn, Randall Dere, Dan Lü, Surai Jones, Cheryl Jones, Yu-Waye Chu, Franck Morschhauser
The Lancet Oncology. 2015335 Citations

Related on ScholarIQ

470M+ articles · free account